These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8582386)

  • 1. At what time are implantable defibrillator shocks delivered? Evidence for individual circadian variance in sudden cardiac death.
    d'Avila A; Wellens F; Andries E; Brugada P
    Eur Heart J; 1995 Sep; 16(9):1231-3. PubMed ID: 8582386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian and seasonal variations of ventricular tachyarrhythmias in patients with early repolarization syndrome and Brugada syndrome: analysis of patients with implantable cardioverter defibrillator.
    Kim SH; Nam GB; Baek S; Choi HO; Kim KH; Choi KJ; Joung B; Pak HN; Lee MH; Kim SS; Park SJ; On YK; Kim JS; Oh IY; Choi EK; Oh S; Choi YS; Choi JI; Park SW; Kim YH; Lee MY; Lim HE; Lee YS; Cho Y; Kim J; Lee DI; Cho DK; Kim YH
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):757-63. PubMed ID: 22353358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Medications and Appropriate Implantable Cardioverter-defibrillator Shocks in Aborted Sudden Cardiac Death Due to Coronary Spasm.
    Sueda S; Kohno H
    Intern Med; 2018 May; 57(10):1361-1369. PubMed ID: 29321418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term results of implantable automatic defibrillator in 43 patients. Analysis of predictive factors of the first electric shock].
    Chevalier P; Kirkorian G; Desseigne P; Atallah G; Champagnac D; Canu G; Claudel JP; Lacet C; Touboul P
    Arch Mal Coeur Vaiss; 1993 Oct; 86(10):1459-64. PubMed ID: 8010844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian variation of sustained ventricular tachyarrhythmias terminated by appropriate shocks in patients with an implantable cardioverter defibrillator.
    Behrens S; Galecka M; Brüggemann T; Ehlers C; Willich SN; Ziss W; Dissmann R; Andresen D
    Am Heart J; 1995 Jul; 130(1):79-84. PubMed ID: 7611127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian variation of malignant ventricular arrhythmias in patients with ischemic and nonischemic heart disease after cardioverter defibrillator implantation. European 7219 Jewel Investigators.
    Englund A; Behrens S; Wegscheider K; Rowland E
    J Am Coll Cardiol; 1999 Nov; 34(5):1560-8. PubMed ID: 10551707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry.
    Tsai VW; Cooper J; Garan H; Natale A; Ptaszek LM; Ellinor PT; Hickey K; Downey R; Zei P; Hsia H; Wang P; Hunt S; Haddad F; Al-Ahmad A
    Circ Heart Fail; 2009 May; 2(3):197-201. PubMed ID: 19808340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian variation of sudden cardiac death reflects age-related variability in ventricular fibrillation.
    Arntz HR; Willich SN; Oeff M; Brüggemann T; Stern R; Heinzmann A; Matenaer B; Schröder R
    Circulation; 1993 Nov; 88(5 Pt 1):2284-9. PubMed ID: 8222123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy.
    Maron BJ; Semsarian C; Shen WK; Link MS; Epstein AE; Estes NA; Almquist A; Giudici MC; Haas TS; Hodges JS; Spirito P
    Heart Rhythm; 2009 May; 6(5):599-602. PubMed ID: 19332391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes and Prevention of Inappropriate Implantable Cardioverter-Defibrillator Shocks.
    Kulkarni N; Link MS
    Card Electrophysiol Clin; 2018 Mar; 10(1):67-74. PubMed ID: 29428143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction.
    Ersbøll M; Valeur N; Andersen MJ; Mogensen UM; Vinther M; Svendsen JH; Møller JE; Kisslo J; Velazquez EJ; Hassager C; Søgaard P; Køber L
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):851-60. PubMed ID: 23850252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.
    Skowasch D; Ringquist S; Nickenig G; Andrié R
    PLoS One; 2018; 13(3):e0194496. PubMed ID: 29566033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
    J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.